Study on epilepsy, neurodevelopmental disorder, and motor disorders associated with mutations in the DHDDS gene

Goal of Study: To examine how mutations in the DHDDS gene (dehydrodolichyl diphosphate synthase) may lead to developmental delays and seizures, with or without movement issues.

Key Points:

• The relationship between the DHDDS gene and its effects on development and seizures is still not fully understood.

• This study looked at how epilepsy and other developmental and movement disorders are linked to mutations in the DHDDS gene, including a detailed report on a child with these mutations.

Study Methods:

• Reviewed existing research related to DHDDS gene mutations.

• Gathered information from a total of 25 cases for analysis.

• Summarized and analyzed the characteristics of the DHDDS gene.

Study Results:

• Epilepsy linked to DHDDS gene mutations usually starts in infancy.

• The first signs of epilepsy often appear as quick, involuntary muscle jerks (myoclonus).

• Epilepsy often occurs alongside developmental delays and intellectual disabilities, but individuals may not show specific movement disorders.

• Brain scans (MRI) typically show no issues, but brain wave tests (EEG) often reveal abnormalities.

• A medication called Valproic acid (VPA) has been found to be effective in treating these seizures.

Conclusion of Study:

• Mutations in the DHDDS gene are linked to a group of rare genetic disorders known as congenital glycosylation disorders (CDG), as well as a type of vision loss called autosomal recessive retinitis pigmentosa and epilepsy.

• CDG includes various rare genetic disorders that affect how sugar molecules (glycans) are added to proteins in our cells, which is important for proper cell function.

• Retinitis pigmentosa is a genetic eye condition that can lead to gradual vision loss. It is called autosomal recessive because it can be inherited from parents, but the child may be the only one affected.

• Valproic acid (VPA) has shown significant positive effects in treatment.